- Home
- ISPC vs NXTS Comparison
ISPC vs NXTS Comparison
Compare ISPC & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPC | NXTS |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | Israel |
| Employees | N/A | 9 |
| Industry | Precision Instruments | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ISPC | NXTS |
|---|---|---|
| Price | $3.84 | $4.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 19.2M | 19.6K |
| Earning Date | 05-18-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,928,998.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $0.55 |
| 52 Week High | $6.77 | $6.21 |
Technical Indicators
Market Signals| Indicator | ISPC | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 56.44 |
| Support Level | $0.37 | $3.92 |
| Resistance Level | $6.77 | $5.31 |
| Average True Range (ATR) | 0.75 | 0.60 |
| MACD | -0.08 | -0.15 |
| Stochastic Oscillator | 57.78 | 29.71 |
Price Performance
Historical ComparisonAbout ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.